IMVT
Immunovant, Inc.
Healthcare · Biotechnology · NMS
$31.11
Data: 2026-05-19
✓ ETHICAL PASS
MOAT
HIGH
Data Confidence: 100.0%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$5.4B
Total market value of the company
0.00
Rev Growth
0.0%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
N/A
Consensus view from ? analysts covering this stock
About Immunovant, Inc.
Company description not available.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% PASS
Debt must be below 33% of total assets
Cash Ratio
18.4% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
9.2%
Historical annualised return based on price data
Days in State
3
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
N/A
52W High
$N/A
52W Low
$N/A
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-20 | PANDE ATUL | Director | 6,000 | $157,740 | |
| 2026-05-20 | PANDE ATUL | Director | 6,000 | $50,580 | |
| 2026-05-01 | SUSMAN ROBERT GRAHAM | Director | 2,502 | $67,979 | |
| 2026-04-23 | GIRÃO TIAGO M | Chief Financial Officer | 25,760 | $763,011 | |
| 2026-04-23 | STOUT JAY S | Chief Technology Officer | 2,754 | $81,573 | |
| 2026-04-08 | STOUT JAY S | Chief Technology Officer | 10,132 | $251,578 | |
| 2026-04-08 | GLORIA MELANIE | Chief Operating Officer | 8,722 | $216,567 | |
| 2026-04-08 | VAN TUYL CHRISTOPHER | Officer | 5,165 | $128,247 | |
| 2026-04-07 | HUGHES DOUGLAS J | Director | 13,880 | — | |
| 2026-04-07 | VENKER ERIC | Chief Executive Officer | 232,252 | — |
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-19